Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where I. Ágoston is active.

Publication


Featured researches published by I. Ágoston.


Value in Health | 2014

Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary.

D Endrei; B. Molics; I. Ágoston

We read with great interest the excellent article of Sussex et al. [1] on a pilot study of multicriteria decision analysis (MCDA) for valuing orphan medicines. MCDA seems to be more important in the past years, and many countries have tried to use it for evaluating new medical technologies [2,3]. We would like to give a short overview on the application of MCDA in Hungary. Hungary can be considered an upper-middle–income country [4]. We run a solidarity-based health insurance system with a single payer, where the National Health Insurance Fund Administration (in Hungarian: Országos Egészségbiztosítási Pénztár [OEP]) is the only health care financing agency [5,6]. All the hospitals—with the exception of church hospitals—are owned by the central government. On behalf of the central government, a governmental public agency, the National Institute for Qualityand Organizational Development in Healthcare and Medicines (in Hungarian: Gyógyszerészeti és Egészségügyi Minőségés Szervezetfejlesztési Intézet [GYEMSZI]) is responsible for the supervision of Hungarian hospitals [7]. The Hungarian health technology assessment (HTA) Office was established in 2004, and it also belongs to GYEMSZI [8,9]. Hungary adopted the directive 89/105/EEC of the Council of the European Communities on transparency for the evaluation of new drugs (2004) and medical devices (2007) applying for health insurance reimbursement [10]. We also have a formal guideline for conducting economic evaluation of health care interventions in Hungary [11]. More detailed description of the Hungarian health care system can be found elsewhere [12–17]. MDCA was introduced in Hungary by a ministerial decree in 2010 for the evaluation of new hospital medical technologies applied in hospital care [18]. In this term, medical technologies do include neither drugs nor medical devices. As a part of the application dossier, one must submit a formal HTA report (including a health-economics analysis), clinical evaluation, clinical expert opinion, and detailed cost calculation. Detailed cost calculation should demonstrate how the new hospital medical technology complies with the special financing methods of the Hungarian hospital care. It means that beyond the cost of new technology, its additional costs (e.g., implantation surgery, hospital stay, and nursing care) must be calculated according to the diagnosis-related groups such as hospital care financing [19,20]. The key players of the decision-making process are the health care financing agency (OEP), HTA office (within GYMESZI), Hungarian Medical College, and Scientific Council in Health Care.


Health Policy | 2014

The effect of performance-volume limit on the DRG based acute care hospital financing in Hungary

D Endrei; Antal Zemplényi; B. Molics; I. Ágoston; I Boncz

OBJECTIVES The aim of our paper is to analyse the effect of the so-called performance volume limit (PVL) financing method on acute hospital care. DATA AND METHODS The data were derived from the nationwide administrative dataset of the National Health Insurance Fund Administration (OEP) covering the period 2003-2008. We analysed the trends in the DRG cost-weights, number of cases, case-mix, and average length of stay. We calculated the average annual reimbursement rate per DRG cost-weight with and without the application of PVL degression according to the hospital type and medical professions. RESULTS Our results showed that although the national case mix (i.e., the sum of all of the DRG cost-weights produced in one year) did not change between 2003-2006, the trend of the annual number of cases increased, and the average length of stay decreased. During 2007-2008, a significant decline was found in each indicator. The introduction of the PVL resulted in a health insurance budget saving of 1.9% in 2004, 2.6% in 2005, 3.4% in 2006, 5.6% in 2007, and 3.2% in 2008. We found the lowest reimbursement rate per DRG cost-weight at the university medical schools (HUF 138,200 or € 550) and childrens hospitals (HUF 132,547 or € 528), whereas the highest was at the county hospitals (HUF 143,451 or € 571) and city hospitals (HUF 142, 082 or € 565). CONCLUSIONS The implementation of the PVL reduced the acute care hospital activity and reimbursement. The effect of the PVL was different on the different types of hospitals, and it had a serious disadvantageous effect on the university medical schools and childrens hospitals.


Value in health regional issues | 2015

The Hungarian Care Managing Organization Pilot Program

I Boncz; Tamás Evetovits; Csaba Dózsa; A Sebestyén; László Gulácsi; I. Ágoston; D Endrei; T Csákvári; Thomas E. Getzen

OBJECTIVES The aim of this article was to provide a description of the Hungarian care managing organization (CMO) pilot program and its environment, incentive structure, and preliminary outcomes. The need to change the behavior of doctors to increase the effectiveness and cost-effectiveness of the system was the key rationale for the Hungarian CMO pilot program. METHODS After an application process, nine CMOs were entitled to enter into the system in July 1999. By 2006, there were 14 CMOs covering 2.1 million people. The Hungarian CMO program tried to combine the advantages of both the US managed care programs and the UK general practitioner fundholding system, within the constraints and opportunities of a Central-European country committed to a single-payer health insurance system. RESULTS The revenue of CMOs derived from a risk-adjusted capitation. The capitation formula was weighted only by age and sex. The expenditures of the CMOs included all the health expenditures on their patients that occurred in any part of the health care system. The average savings rate for all CMOs for the fiscal years 1999 to 2007 was 4.94%. The highest rates of savings were realized in chronic and acute inpatient care and medical devices. The pilot was discontinued in 2008 without a comprehensive evaluation of the experience. CONCLUSIONS We can conclude that this pilot had a significant contribution to the modernization of the Hungarian health care system.


International Journal of Cancer | 2018

Cancer screening policy in Hungary: Letter to the Editor

Zsuzsanna Kívés; Krisztina Juhász; T Csákvári; I. Ágoston; D Endrei

Dear Editor, Basu et al. published an excellent overview on the status of implementation and organization of cancer screening in the European Union Member States. This paper provides a valuable description of current cancer screening policies of the European countries. We would like to give some detailed information on the Hungarian screening programs. Mammography-based breast cancer screening has a long tradition in Hungary. Mammography-based opportunistic breast cancer screening started in Hungary as early as the late 1960s in the city of Bonyh ad. Even the first scientific evidences for the effectiveness of mammography screening in reducing the breast cancer mortality came from large randomized controlled trial performed by a Hungarian radiologist, Prof. L aszl o Tab ar, in two Swedish counties, Kopparberg and € Osterg€otland. Later several mammography screening pilot programs were performed in Hungary. Following the evaluation of pilot programs for mammography screening, a nationwide, organized population based breast cancer screening program was announced in 2001 and started in January 2002. Unlike the ones (45–64 years) given in table 2 of the paper by Basu and coworkers, women aged between 45 and 65 years old were invited for participating in the breast cancer screening program. Opportunistic cervical cancer screening started in Hungary during the 1970s. One should bear in mind that at that time Hungary was a socialist country, behind the “iron curtain” with limited access to the achievements of the developed countries. After the socialist system collapsed in 1990, Hungary initiated new pilot program for the early detection of cervical cancer. This program was financed by the World Bank. After three decades of opportunistic cervical cancer screening activities, an organized, nationwide cervical cancer screening was introduced in Hungary in July 2003 for women aged between 25 and 65 years old. Although in figure 2 of the paper mentioned that the Hungarian cervical cancer screening program’s rollout ongoing, we would like to emphasize that rollout was completed. However, we have several problems with the low participation rate of invited women: “The Hungarian organized, nationwide cervical screening program managed to moderately increase (13.7%) the screening coverage of the target population in the first screening round; therefore, it failed to attract women with high risk outside of the scope of both the previous opportunistic and the newly introduced organized cervical cancer screening program.” Between 2013 and 2015, a new element was added to the organized cervical cancer screening program, in order to increase the participation rate. A pilot program was introduced in 2013 for the involvement of health visitors. It meant that in addition to gynecologists, health visitors, having a B.Sc. degree in health sciences, were allowed to take the smears. The involvement of health visitors resulted in 8.3% increase in the participation rate. In Hungary, we had several pilot programs for colorectal cancer screening. In 1997–1998, the first Hungarian colorectal cancer screening pilot program was done in a well-defined administrative area of the Capital, Budapest, with support from the World Bank Close the gap public health programme. The next colorectal cancer screening pilot program was organized in a small city of Ajka, and the surrounding area in 2003– 2004. Later some other small scale pilot programs were organized in different Hungarian cities (Balatonf€ ured, B ek escsaba, Kecskem et, Nagyat ad). In 2015, we had a new colorectal cancer screening pilot program in County Csongr ad, financed from European Union’s funding (“Social Renewal Operational Programme: SROP-6.1.3A-13/1–2013-0001 To support the extension of pilot screening programs—cervical cancer screening by health visitor and colorectal cancer screening programs”). These pilot programs used immunochemical fecal occult blood test (FOBT) for the early detection of fecal blood. Following the evaluation of this pilot program, Hungarian health policy leaders committed to the introduction of a nationwide colorectal cancer screening program. We hope this program will be launched as soon as possible. Hungary can be considered as a pioneer with the application of immunochemical testing for colorectal cancer. But in Hungary we still did not have a nationwide colorectal cancer program, as it was stated in figure 3. The legal regulation of colorectal cancer screening was a bit confusing in Hungary. Since 1997, a ministerial decree regulates both the opportunistic and nationwide organized screening programs in Hungary. This decree defines breast and cervical cancer screening as an organized, nationwide screening program. Colorectal cancer screening program was mentioned as an organized, nationwide screening program in Hungary on a single day, the December 31, 2005! Never before or after this day colorectal cancer screening was not an organized, nationwide screening program, only opportunistic and/or pilot programs were carried out. We emphasize that the current Hungarian legal regulation (law) also does not mention colorectal cancer screening among the nationwide, organized cancer screening programs. Regarding cancer screening programs, we should mention their cost-effectiveness. In a country, with limited resources for healthcare, financial issues are important. In 2001–2002, Le tt er to th e E di to r


Value in Health | 2015

Experiences with Price Competition of Biosimilar Drugs In Hungary in Case of Colony-Stimulating Factor Products

L Hornyák; Z Nagy; Z Tálos; D Endrei; I. Ágoston; T Csákvári; I Boncz

value-based pricing, which reflects disease burden, therapeutic innovation, and social values, is suggested. This study attempts to measure the importance of costeffectiveness and other values for a new anticancer drug. Methods: Through literature reviews and experts’ advices, eight health insurance benefit criteria were selected: disease severity, size of population affected by disease, pediatric medicine, alternative drugs, innovativeness, clinical benefit, cost-effectiveness, and budget impact. Preference for the criteria was investigated by using Discrete Choice Experiments(DCE), Analytic Hierarchy Process (AHP), swing weighting (SWING), and direct point allocation (DIRECT). The survey was conducted in three hundred general population through face to face interview. Respondents were selected using stratified random sampling by age, sex and region. The conditional logistic regression for DCE was conducted with STATA ver.12. Results: In the preference investigation using DCE, people preferentially considered disease severity (OR: 1.837, 95% CI: 1.673 to 2.017), alternative drugs (OR: 1.556, 95% CI: 1.458 to 1.661), and size of population affected by disease (OR: 1.408, 95% CI: 1.285 to 1.543). According to the results by using AHP, respondents considered clinical benefit to be the most important, followed by cost-effectiveness and disease severity as the main evaluation items. As estimated by SWING and DIRECT, clinical benefit was also evaluated as the most important item. There was no difference in the first to third priority evaluation items between SWING and DIRECT. ConClusions: The priorities derived from all methodologies show that clinical benefit and disease severity were more important than cost-effectiveness in general terms. In the situation where decision-making is mostly centered on cost-effectiveness, our results may be seen as the social demand that clinical benefit and the influence of applicable disease should be reflected appropriately in the insurance coverage.


Orvosi Hetilap | 2014

Az otthoni szakápolás egészségbiztosí tási vonatkozásainak elemzése Magyarországon

Zoltan Horvath; A Sebestyén; B. Molics; I. Ágoston; D Endrei; A Oláh; J Betlehem; László Imre; Gabriella Bagosi; I Boncz

Bevezetes: Az otthoni szakapolas 1996 vegen indult meg Magyarorszagon. Celkitűzes: A szerzők celja a magyar otthoni szakapolasi rendszer egeszsegbiztositasi es igenybeveteli mutatoinak bemutatasa. Modszer: Az elemzesben szereplő adatok az Orszagos Egeszsegbiztositasi Penztar finanszirozasi adatbazisabol (2001–2012) szarmaznak. Elemeztek a betegszamokat, a vizitszamokat, a szakapolasi es szakiranyu terapias tevekenysegek (gyogytorna, fizioterapia, logopedia) aranyat. Eredmenyek: Az ellatott betegek szama a 2001. evi 36 560-rol 2012-re 51 647-re nőtt, 41,3%-kal emelkedett. A teljesitett vizitek szama ugyanezen időszak alatt 841 715-ről 1 194 670-re, 41,9%-kal nőtt. A szakapolasi es szakiranyu terapias tevekenysegek, valamint az apolasi fokozatok vonatkozasaban jelentős megyek kozotti eltereseket figyeltek meg. A szakapolasra kifizetett osszegek aranya a legmagasabb volt Nograd (80,4%), Szabolcs-Szatmar-Bereg (79,7%) es Komarom-Esztergom (74,6%) megyekben, mig a legalacsonyabb Zala (53,0%) es Csongrad (52,7%...INTRODUCTION Home nursing care was introduced in Hungary in 1996. AIM The aim of this study was to analyse health insurance data and utilization indicators of the Hungarian home nursing care. METHOD Data derived from the database of the National Health Insurance Fund Administration (2001-2012). The number of patients and visits, and the ratio of special nursing and special therapy (physiotherapy, speech therapy) were analysed. RESULTS The number of patients increased by 41.3% from 36.560 (2001) to 51.647 (2012). The number of visits also increased by 41.9% from 841.715 (2011) to 1.194.670 (2012). Significant geographical inequalities were found in the ratio of special nursing and special therapy as well as nursing needs. The ratio of reimbursement for special nursing was the highest in county Nógrád (80.4%), Szabolcs-Szatmár-Bereg (79.7%) and Komárom-Esztergom (74.6%), while the lowest in county Zala (53.0%), Csongrád (52.7%) and Budapest (47.9%). CONCLUSIONS There are significant inequalities in the home nursing care in Hungary. In order to decrease these inequalities, specific guidelines should be developed for home nursing care.


Orvosi Hetilap | 2014

Health insurance data analysis on home nursing care in Hungary

Zoltan Horvath; A Sebestyén; B. Molics; I. Ágoston; D Endrei; A Oláh; J Betlehem; László Imre; Gabriella Bagosi; I Boncz

Bevezetes: Az otthoni szakapolas 1996 vegen indult meg Magyarorszagon. Celkitűzes: A szerzők celja a magyar otthoni szakapolasi rendszer egeszsegbiztositasi es igenybeveteli mutatoinak bemutatasa. Modszer: Az elemzesben szereplő adatok az Orszagos Egeszsegbiztositasi Penztar finanszirozasi adatbazisabol (2001–2012) szarmaznak. Elemeztek a betegszamokat, a vizitszamokat, a szakapolasi es szakiranyu terapias tevekenysegek (gyogytorna, fizioterapia, logopedia) aranyat. Eredmenyek: Az ellatott betegek szama a 2001. evi 36 560-rol 2012-re 51 647-re nőtt, 41,3%-kal emelkedett. A teljesitett vizitek szama ugyanezen időszak alatt 841 715-ről 1 194 670-re, 41,9%-kal nőtt. A szakapolasi es szakiranyu terapias tevekenysegek, valamint az apolasi fokozatok vonatkozasaban jelentős megyek kozotti eltereseket figyeltek meg. A szakapolasra kifizetett osszegek aranya a legmagasabb volt Nograd (80,4%), Szabolcs-Szatmar-Bereg (79,7%) es Komarom-Esztergom (74,6%) megyekben, mig a legalacsonyabb Zala (53,0%) es Csongrad (52,7%...INTRODUCTION Home nursing care was introduced in Hungary in 1996. AIM The aim of this study was to analyse health insurance data and utilization indicators of the Hungarian home nursing care. METHOD Data derived from the database of the National Health Insurance Fund Administration (2001-2012). The number of patients and visits, and the ratio of special nursing and special therapy (physiotherapy, speech therapy) were analysed. RESULTS The number of patients increased by 41.3% from 36.560 (2001) to 51.647 (2012). The number of visits also increased by 41.9% from 841.715 (2011) to 1.194.670 (2012). Significant geographical inequalities were found in the ratio of special nursing and special therapy as well as nursing needs. The ratio of reimbursement for special nursing was the highest in county Nógrád (80.4%), Szabolcs-Szatmár-Bereg (79.7%) and Komárom-Esztergom (74.6%), while the lowest in county Zala (53.0%), Csongrád (52.7%) and Budapest (47.9%). CONCLUSIONS There are significant inequalities in the home nursing care in Hungary. In order to decrease these inequalities, specific guidelines should be developed for home nursing care.


Value in Health | 2009

PHP84 REGIONAL DIFFERENCES IN ACUTE CARE HOSPITAL BED CAPACITIES FOLLOWING THE 2006–2008 HEALTH CARE REFORM IN HUNGARY

G Vas; I. Ágoston; Z Nagy; A Sebestyén; I Kriszbacher; J Betlehem; S Varga; I Boncz

PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW Gaebel K, Kaulback K, Robertson D, Blackhouse G, Xie F, Assasi N, Goeree R McMaster University, Hamilton, ON, Canada OBJECTIVES: In the 2001 policy statement from the American College of Emergency Physicians, they considered a large number of conditions as primary indications for emergency ultrasonography (US). Early trials of US did not take place in emergency departments (EDs) and the US interpreter was not an emergency physician (EP). The objective of this review was to determine if there is evidence to evaluate whether US conducted by non-radiologists in a small emergency department is an effective diagnostic tool. METHODS: A systematic review was conducted to identify health technology assessments (HTAs), systematic reviews (SRs), meta-analyses (MAs), randomized controlled trials (RCTs), and controlled clinical trials published in the last 5 years. RESULTS: The search identified nine trials, and two systematic reviews. The primary indications in these reports were: trauma, deep vein thrombosis (DVT), pain, undifferentiated hypotension and US-guided procedures. Reports regarding US-guided procedures took place in small EDs and the success rates of US-guided cannulation were significantly larger compared to the traditional technique. Sensitivity and specificity estimates for EP performed US in the diagnosis of trauma, and DVT are high, and similar to those reported when radiologists interpreted the US scans. The addition of US in diagnosing pelvic pain increases physician confidence and was especially valuable in the evaluation of a patient who is also obese. The addition of an US protocol to standard care afforded physicians the ability to compile a significantly shorter and more accurate list of possible causes of non-traumatic undifferentiated hypotension. These results are inferred from trials from large urban hospitals. CONCLUSIONS: Diagnostic estimates obtained when EPs perform the US are comparable to those obtained when the US was performed by a radiologist. US is an effective tool in the hands of EPs in EDs, both small and large.


Orvosi Hetilap | 2014

Az otthoni szakápolás egészségbiztosítási vonatkozásainak elemzése Magyarországon@@@Health insurance data analysis on home nursing care in Hungary

Zoltan Horvath; A Sebestyén; B. Molics; I. Ágoston; D Endrei; A Oláh; J Betlehem; László Imre; Gabriella Bagosi; I Boncz

Bevezetes: Az otthoni szakapolas 1996 vegen indult meg Magyarorszagon. Celkitűzes: A szerzők celja a magyar otthoni szakapolasi rendszer egeszsegbiztositasi es igenybeveteli mutatoinak bemutatasa. Modszer: Az elemzesben szereplő adatok az Orszagos Egeszsegbiztositasi Penztar finanszirozasi adatbazisabol (2001–2012) szarmaznak. Elemeztek a betegszamokat, a vizitszamokat, a szakapolasi es szakiranyu terapias tevekenysegek (gyogytorna, fizioterapia, logopedia) aranyat. Eredmenyek: Az ellatott betegek szama a 2001. evi 36 560-rol 2012-re 51 647-re nőtt, 41,3%-kal emelkedett. A teljesitett vizitek szama ugyanezen időszak alatt 841 715-ről 1 194 670-re, 41,9%-kal nőtt. A szakapolasi es szakiranyu terapias tevekenysegek, valamint az apolasi fokozatok vonatkozasaban jelentős megyek kozotti eltereseket figyeltek meg. A szakapolasra kifizetett osszegek aranya a legmagasabb volt Nograd (80,4%), Szabolcs-Szatmar-Bereg (79,7%) es Komarom-Esztergom (74,6%) megyekben, mig a legalacsonyabb Zala (53,0%) es Csongrad (52,7%...INTRODUCTION Home nursing care was introduced in Hungary in 1996. AIM The aim of this study was to analyse health insurance data and utilization indicators of the Hungarian home nursing care. METHOD Data derived from the database of the National Health Insurance Fund Administration (2001-2012). The number of patients and visits, and the ratio of special nursing and special therapy (physiotherapy, speech therapy) were analysed. RESULTS The number of patients increased by 41.3% from 36.560 (2001) to 51.647 (2012). The number of visits also increased by 41.9% from 841.715 (2011) to 1.194.670 (2012). Significant geographical inequalities were found in the ratio of special nursing and special therapy as well as nursing needs. The ratio of reimbursement for special nursing was the highest in county Nógrád (80.4%), Szabolcs-Szatmár-Bereg (79.7%) and Komárom-Esztergom (74.6%), while the lowest in county Zala (53.0%), Csongrád (52.7%) and Budapest (47.9%). CONCLUSIONS There are significant inequalities in the home nursing care in Hungary. In order to decrease these inequalities, specific guidelines should be developed for home nursing care.


Value in Health | 2009

PHP7 BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS

S Varga; M Gresz; I. Ágoston; G Vas; A Sebestyén; J Betlehem; I Kriszbacher; Z Nagy; I Boncz

therewith is price elastic. We estimate that approximately 40% of the increase in prescription volume results from REGO. Additionally to the increase in expenditures the sickness funds are facing a loss of income as less co-payment rates are paid. Prescriptions with prices lower than the co-payment rate are not paid by the insured anymore, but by the sickness funds. These low-price prescriptions cause a dramatic increase in volume, however, not a decisive increase in total expenditures. CONCLUSIONS: The time courses allow us to evaluate the effects of REGO. Furthermore they reveal information about the behaviour of the demand function, when the price drops to zero. The intention of REGO is to improve equity by protecting poorer and heavy users of prescription drugs from the financial burden of co-payments. Demand increases, when REGO reduces the price for prescription drugs to a 0. This could indicate an improvement in equity and access, however, affects on efficiency have to be shown in further analysis.

Collaboration


Dive into the I. Ágoston's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Z Nagy

University of Pécs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge